Dynamics of adiponectin and leptin levels in patients with metabolic syndrome treated with complex therapy including intravenous laser blood irradiation
https://doi.org/10.37895/2071-8004-2019-23-1-12-15
Abstract
The given paper presents results of the trial studying effects of intravenous laser blood irradiation (ILBI) at adiponectin and leptin dynamics in patients with metabolic syndrome (MS). 154 patients with MS (mean age 36,5 ± 3,6 years) were examined and treated. All patients were randomly divided into 2 groups: control (32 patients) and main (122 patients). Patients in the control group were treated according to MS treatment standards: lipid-lowering therapy, hypoglycemic agents, antihypertensive therapy. Patients from the main group had a course of intravenous laser therapy according to ILBI-405 technique instructions in combination with medicamentous therapy. Laser device «Matrix – VLOK» (Matrix Ltd, Russia) with wavelength 0,405 μm, output power at the end of main fiber tip 1–1.5 mW was used. ILBI session lasted for 15 minutes in a continuous mode; treatment course consisted of 10 daily sessions except weekends. Adiponectin and leptin levels were determined using the enzyme immunoassay set manufactured by BioVendor as well as with enzyme immunoassay and enzyme immunoassay analyzer Victor (PerkinElmer Ltd) with wavelength 450 nm. As it has been shown, ILBI included into comprehensive therapy normalizes adiponectin and leptin parameters.
About the Authors
N. M. Burduli
North Ossetian State Medical Academy
Russian Federation
Vladikavkaz
Russian Federation
Vladikavkaz
T. G. Gaitova
North Ossetian State Medical Academy
Russian Federation
Vladikavkaz
Russian Federation
Vladikavkaz
References
1. Balkarov I. Obesity and arterial hypertension // Vrach. 2003; 9: 22–26.
2. Butrova S.A. Metabolic syndrome: pathogenesis, clinical picture, diagnosis, treatment approaches // Russky meditzinsky zhurnal. 2001; 9 (2): 56–76.
3. Consensus of Experts on an interdisciplinary approach to the management, diagnosis and treatment of patients with metabolic syndrome // Kardiovaskuliarnaya terapia i profilaktika. 2013; 12 (6): 41–82.
4. Roitberg G.E. Metabolic syndrome. M.: MEDPress-Inform. 2007: 224.
5. Usmonzoda D.U., Achilov A.A., Lebedeva O.D. et al. Laser therapy for treating disorders of lipid metabolism refractory to lipid-lowering therapy and in ischemic heart disease // Lasernaya Medicina. 2011; 15 (1): 25–28.
6. Fox C.S., Massaro J.M., Hoffmann U. et al.Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart study // Circulation. 2007; 116 (1): 39–48.
7. Ragin C.C., Dallal C., Okobia M. et al.Leptin levels and leptin receptor polymorphism frequency in healthy populations // Infect. Agent Cancer. 2009; 10 (4); 1: 13.
8. Staiger K., Stefan N., Staiger H. et al. Adiponectin is functionally active in human islets but does nott affect insulin secre-tory function or beta-cell lipoapoptosis // J. Clin. Endocrinol. Metab. 2005; 90: 6707–6713.
Review
For citations:
Burduli N.M., Gaitova T.G. Dynamics of adiponectin and leptin levels in patients with metabolic syndrome treated with complex therapy including intravenous laser blood irradiation. Laser Medicine. 2019;23(1):12-15. (In Russ.) https://doi.org/10.37895/2071-8004-2019-23-1-12-15
Views:
144
Email this article 